The inactivation of the p53 and Rb pathways would account for the majority of human tumours. There are many levels of cross talk between p53 and Rb that have been identi®ed. However, the identi®cation of the mdm2-Rb interaction established a closer link between the two most well studied tumour suppressors, p53 and Rb. Recent studies of the novel trimeric complex Rb-mdm2-p53 provided us with a functional insight of how the two tumour suppressors can act together in regulating p53 induced apoptosis. Beginning with the properties of the Rb-mdm2-p53 trimeric complex, we shall review the propounding evidence suggesting that the apoptotic function of p53 is linked to its transrepression function. The uncoupling of the apoptotic function and transactivation function of p53 will also be discussed.
Introduction
Most human tumours have defects in either the p53 or Rb pathways. Rb is one of the best-studied tumour suppressors and functional inactivation has been associated with the development of retinoblastoma and other cancers (Lee et al., 1987; Marshall, 1991; Weinberg, 1995) . In addition to Rb, the other frequently mutated tumour suppressor is p53. Discovered in 1979 (Lane and Crawford, 1979; Linzer and Levine, 1979) , p53 has been shown to be mutated in more than 50% of human cancers (Hollstein et al., 1991) . Furthermore, p53 knock-out mice have been shown to have an increased tumour formation (Donehower et al., 1992) . A germ line mutation in p53 has also been detected in the patients who suer from the cancer prone Li-Fraumani syndrome (Malkin et al., 1990) . Interestingly, viral proteins are also known to interact with and inhibit the tumour suppression function of both p53 and Rb (Dyson et al., 1989; Eliyahu et al., 1989; Finlay et al., 1989; Lane and Crawford, 1979; Linzer and Levine, 1979; Nevins, 1992) . Mutation or inactivation of both tumour suppressors have also been found in a variety of human tumours (Levine, 1990; Levine and Momand, 1990; Levine et al., 1991; Sherr, 1996; Weinberg, 1995) and often have further negative eects resulting in increased tumour recurrence and decrease survival of patients as compared to mutations in only one tumour suppressor alone. These argue for the cooperative eect of p53 and Rb in tumour suppression (Cordon-Cardo et al., 1997; Xu et al., 1995) .
Rb is important in controlling the progression of the cell cycle from G1 phase to S phase, principally by binding to and inactivating the E2F transcription factors (Chellappan et al., 1991) . This interaction of Rb with E2F can be negatively regulated by viral oncoproteins containing the LXCXE motif, such as E1A of adenovirus, large T of SV40 and E7 of human papilloma virus (Nevins, 1992; Weinberg, 1995) as well as other cellular proteins such as D-type cyclins (Dowdy et al., 1993) . In the cell, Rb is regulated via phosphorylation by cell cycle-dependent kinases (CDKs) and cyclins, which in turn is inhibited by the cell cycle inhibitor, p21 cip1/waf1 (Mittnacht, 1998) . The identi®cation of p21 waf1/cip1 as a p53 target gene implicated p53 in the upstream control and regulation of Rb (El-Deiry et al., 1993; Harper et al., 1993) .
Apart from being a cell cycle regulator, the tumour suppressor p53 also plays an important role in the induction of apoptosis in response to DNA damage (Clarke et al., 1993; Lowe et al., 1993) . It was demonstrated that p53 could function as a transcription factor (Field and Jang, 1990; Raycroft et al., 1990) and the mdm2 gene is one of its targets (Barak et al., 1993; Momand et al., 1992; Oliner et al., 1993) . It is argued that mdm2 is also a critical cellular inhibitor of p53 function as mdm2 knock out mice are embryonic lethal but this is rescued in a p53 null background (de Oca Luna et al., 1995; Jones et al., 1995) . Once induced by p53, the oncoprotein mdm2 is known to interact with, inhibit p53 as well as target p53 for degradation thereby exhibiting negative feedback with respect to p53 activity (Barak et al., 1993; Bottger et al., 1997; Chen et al., 1996b; Haupt et al., 1996 Haupt et al., , 1997 Lin et al., 1994; Momand et al., 1992; Oliner et al., 1993; Picksley et al., 1994) . p53 has also been shown to repress many cellular and viral promoters which do not contain p53 binding sites (Ko and Prives, 1996) . This includes the genes encoding c-fos and SV40 large T antigen (Ginsberg et al., 1991; Mack et al., 1993; Subler et al., 1992) .
Interestingly, mdm2 has also been found to bind to Rb (Xiao et al., 1995) . In contrast to the mdm2-p53 interaction, very little is known about the biological eect of the mdm2-Rb interaction. The ®nding that the transactivation function of E2F1 may be stimulated by mdm2 suggested that the mdm2-Rb interaction may promote cell growth (Xiao et al., 1995) . However, a direct interaction between mdm2 and E2F1/DP1 has also been reported to stimulate the transactivation function of E2F1 in Saos-2 cells which express an mdm2 binding defective Rb (Martin et al., 1995) . It is presently unclear whether this increased transactivation function of E2F1 in the presence of mdm2 is dependent on mdm2-Rb binding. Neverthless, the mutational spectra of the Rb gene implicated that mdm2-Rb interaction is often lost in human tumours. Unlike p53 gene, missence mutation in Rb is rare and no mutational`hotspots' can be identi®ed in the Rb gene (Lohmann et al., 1996) ; most of the mutations are distributed throughout 24 of the 27 exons in the Rb gene of hereditary retinoblastomas (Harbour, 1998) . Furthermore, the majority of Rb mutations are nonsense or frameshift mutations in the coding region resulting in a premature termination (Harbour, 1998; Lohmann et al., 1996; Wadayama et al., 1994) and this often results in a loss or great reduction in Rb expression. This is consistent with the hypothesis that Rb is a protein assembly factor and other protein interactions such as c-Abl-Rb (Welch and Wang, 1993) and mdm2-Rb (Xiao et al., 1995) , not just the E2F-Rb (Nevins, 1992) , are also important for its tumour suppression function.
A recent report by Hsieh et al. (1999) may now shed some light on the biological relevance of the mdm2-Rb interaction. It was reported that this mdm2-Rb interaction plays an important role in regulating the stability and apoptotic function of p53 (Figure 1 ). This could be achieved when Rb, mdm2 and p53 were in complex together. It would be appropriate therefore to begin by discussing evidence supporting the identification of this novel trimeric complex. Besides demonstrating the biological role of the mdm2-Rb interaction, the trimeric complex model shows how a physiological regulator such as Rb may modulate the regulation of p53 by mdm2. Also evident from such studies was the conclusion that the transactivation ability of p53 can be uncoupled from its apoptotic ability but there is a correlation between the transrepression activity of p53 and its apoptotic function. In this review, we discuss the contribution of the trimeric complex in strengthening the paradigm that apoptotic function of p53 can be uncoupled from its transactivation and that the transrepression ability of p53 correlates with its apoptotic function, thus pointing the way down the path less trod.
The Rb-mdm2-p53 trimeric complex and its physiological implications
Using an in vitro system, it was demonstrated that the binding of Rb and p53 to mdm2 was sterically feasible. Furthermore, it was shown by the use of mutants that the ability of Rb to be immunoprecipitated with p53 was not due to its direct interaction with p53 but due to the ability of mdm2 to act as a bridge resulting in the formation of a trimeric complex involving p53, mdm2 and Rb (Figure 1 ). This suggested that the modulation of mdm2, the best known physiological inhibitor of p53, could occur through a cellular regulator such as Rb. Using wild type Rb or de®ned mutants of Rb, it was further shown that the binding of mdm2 is indeed essential and sucient for Rb to overcome the anti-apoptotic function of mdm2 and also to prevent mdm2-mediated p53 degradation. Rb does not promote mdm2 degradation nor does Rb disrupt the p53-mdm2 interaction, instead forms a trimer with p53 through mdm2 binding. Unlike the product of the Ink4a/ARF locus, ARF (Pomerantz et al., 1998; Stott et al., 1998; Zhang et al., 1998) , the Rbmdm2 interaction does not prevent mdm2 from inhibiting p53-mediated transactivation of various p53 responsive promoters. Since Rb speci®cally rescues the Figure 1 The trimeric complex model mdm2 forms a bridge over the two tumour suppressors p53 and Rb. This allows Rb to selectively modulate the stability and the function of p53 via regulating mdm2 mdm2 bridges the tumour suppressors, p53 and Rb DBS Yap et al apoptotic function but not the transcriptional activity of p53 from negative regulation by mdm2, it may be concluded that transactivation by wild type p53 is not required for the apoptotic function when p53 is in the trimeric complex. Interestingly, using an Rb mutant which only contains the C-pocket region of Rb, it was shown that the Rb, mdm2 and p53 trimeric complex remains active in p53-mediated transrepression, suggesting a link between the transrepression and apoptotic functions of p53. Thus the novel trimeric complex of p53, mdm2 and Rb illustrates another important level of control of p53 and is the ®rst example of how the apoptotic function of wild type p53 can be uncoupled from its transactivation but associated with its transrepression function by a physiological regulator such as Rb. Given that Rb is able to inhibit the negative regulation of mdm2 on p53 induced apoptosis, one would propose that in this trimeric complex model, the loss of mdm2 binding would result in an impaired tumour suppression function of Rb. This is in contrast with the prevailing model proposing that the oncogenic mdm2 can counteract the tumour suppression function of Rb by stimulating the transactivation function of its downstream target E2F1. According to the trimeric complex model, there is a selective pressure for the loss of mdm2 binding to Rb. Consistent with this model, patients with a mutant Rb lacking 58 amino acids of the C-terminus (exons 24 and 25) suer from retinoblastoma but with only a low penetrance (35% of the eyes at risk) because although the mutant Rb can still bind E2F, binding to mdm2 is lost (Bremner et al., 1997) . The low penetrance of the phenotype suggests that although the mdm2-Rb interaction may be important in tumour suppression, the major function of Rb is the negative regulation of E2F.
Further physiological implication for the role of Rbmdm2-p53 trimeric complex in tumour suppression comes from the detection of mdm2 splice variants in high-grade glioblastomas and late-stage ovarian tumours (Matsumoto et al., 1998; Sigalas et al., 1996) . Occurring almost exclusively in malignant tumours, these splice variants are also present with the full length mdm2 (FL mdm2) transcript. Significantly, it was found that all the splice variants of mdm2, when individually cloned and transfected into NIH3T3 cells, which express wild type p53 and Rb, generated transformed foci at high frequency. This was surprising as, with the exception of mdm2-e, all other splice variants were found to be defective in p53 binding in vitro (Sigalas et al., 1996) . Why some of these splice variants are oncogenic may be partly explained by the trimeric complex model. Splice variants which are unable to bind p53 but retain the Rb binding region, might sequester Rb leaving FL mdm2, made from full-length transcripts, to bind p53 in apoptotically inert complexes.
The best-studied role of Rb is its ability to bind and inactivate the transcription factors E2F. Uncontrolled E2F1 expression may cause p53-dependent and -independent apoptosis (Hsieh et al., 1997; Phillips et al., 1997; Qin et al., 1994; Shan and Lee, 1994; Wu and Levine, 1994) and Rb can inhibit apoptosis induced by unrestrained E2F1 expression in cell cultures (Hsieh et al., 1997; Qin et al., 1994) . It was previously reported that apoptosis in dierent tissues of Rb null mice could be either p53-dependent or p53-independent (Holmberg et al., 1998; Macleod et al., 1996) . Analysis of Rb and E2F1 double knock-out and single knock-out mice suggested that the increased apoptosis in Rb null mice was mainly caused by the apoptotic function of E2F1 (Tsai et al., 1998) . The ability of the E2F1 null background to reduce apoptosis in the lens tissue of Rb null mice demonstrated that previously reported p53-dependent apoptosis seen in the lens tissue of Rb null mice (Morgenbesser et al., 1994) could be due to the deregulated apoptotic function of E2F1 (Tsai et al., 1998) since E2F1 is the upstream regulator of the apoptotic function of p53 (Pan et al., 1998) . Together, it is clear that E2F1 may act independently as well as upstream of p53 to induce apoptosis (Pan et al., 1998; Tsai et al., 1998) . These ®ndings also suggest that the inhibitory activity of Rb on p53 mediated apoptosis could be mediated through E2F1. Thus, the apoptosis detected in Rb knock-out mice represents the ®nal balance of loss of the two known activities of Rb: the ability to inhibit E2F1 induced apoptosis and the ability to counteract the inhibitory eect of mdm2 on p53 mediated apoptosis. This re¯ects the dual roles of Rb being both a negative regulator of E2F1 as well as a physiological regulator of the apoptotic function of p53 via mdm2. These relationships are represented in Figure 2 . As the major function of Rb is its ability to negatively regulate the activities of E2F1, it is hardly surprising that an increase rather than a decrease in apoptosis was detected in Rb knock-out mice. Although the ability of Rb to regulate the apoptotic function of p53 may not play a vital role during the normal development, it could be important in response to cellular stress. In line with this, it has been shown recently that stress signals such as hypoxia can induce hypophosphorylation of Rb (Amellem et al., 1996; Krtolica et al., 1998) . Interestingly, mdm2 preferentially binds to the hypophosphorylated form of Rb (Hsieh et al., 1999; Xiao et al., 1995) . Therefore, one would predict that in response to certain stress signals, there should be an increase in the amount of Rb- Figure 2 The central role of Rb as a cellular modulator of apoptosis mdm2 bridges the tumour suppressors, p53 and Rb DBS Yap et al mdm2-p53 trimeric complex which would account for the increased stability and apoptotic function of p53 even in the presence of mdm2.
Rb Apoptosis
Although recent data has shown that DNA damage can result in a phosphorylation of the Ser 15 of p53 which abolishes its interaction with mdm2 (Shieh et al., 1997) , this does not necessarily preclude the formation of the trimeric complex as it was also shown that this modi®cation of p53 does not occur in all DNA damage-induced p53; the p53-mdm2 complex was still detected in the same cell lysate in which the phosphorylation of p53 was also reported (Shieh et al., 1997) . The ability to detect a more prominent Rb, p53 and mdm2 trimeric complex in DNA damaged cells as compared to the untreated cells suggests that the trimeric complex may play an important role in regulating p53-mediated apoptosis in response to DNA damage. The proposed model is consistent with the ®nding that there is a discordance between the amount of p53 produced on DNA damage and its ability to transactivate its target genes such as p21
Waf1/cip1 or mdm2 . This is because the p53 in the trimeric complex would still be competent to induce apoptosis but not transactivation. This installs Rb as an upstream regulator of p53-mediated apoptosis. In this context, one would hypothesize a synergy between the two tumour suppressor pathways and that tumour cells containing both mutant p53 and mutant Rb would respond the worst to radiotherapy and chemotherapy regimes. Consistent with this view, it has been reported that individuals with non-small-cell lung carcinoma had a shorter survival (12 months) if the tumours express theoretically the worst pattern of p53 and Rb staining (Rb negative and p53 positive, indicative of a loss of Rb and mutation in p53) when compared to the individuals (46 months survival) with tumours expressing the normal pattern of p53 and Rb staining (Rb positive and p53 negative, typical of wild type p53 and Rb) (Xu et al., 1994) . This clinical data substantiates a cooperation between the tumour suppressor pathways of p53 and Rb and in toto proposes that the ability of Rb to regulate p53-mediated apoptosis may play an important role in the response of tumours to radiotherapy and chemotherapy.
The mdm2-Rb interaction and its eect on the stability of p53
Recent data showed that mdm2 targeted p53 for degradation via the ubiquitin-proteosome pathway (Bottger et al., 1997; Haupt et al., 1997; . However, Rb binding to mdm2 in the trimeric complex blocked the ability of mdm2 to target p53 for degradation. This leads to a stabilization of p53 even in the presence of mdm2. Recent experiments have shown that ARF also interacts with mdm2 and can protect p53 from mdm2-mediated degradation (Pomerantz et al., 1998; Stott et al., 1998; .
Although the molecular mechanisms of how p53 can be protected from mdm2 targeted degradation in the Rb-mdm2-p53 trimeric complex is not known, it is notable that the Rb binding site on mdm2 (residues 272 ± 320) is located in the region which is required to mediate p53 degradation. An mdm2 mutant, deleted between residues 220 ± 437, has been shown to be incapable of mediating p53 degradation despite still being able to bind p53 . It is therefore possible that Rb may protect p53 from mdm2 targeted degradation by occupying a site on mdm2 conferring sensitivity to degradation. Alternatively, Rb may compete with some other proteins involved in the degradation pathway which bind to the same or similar sites of mdm2 to mediate its ability to target p53 for degradation (Figure 1) . The ability of Rb to prevent protein degradation through proteinprotein interaction has been demonstrated with E2F1 (Campanero and Flemington, 1997; Hateboer et al., 1996; Hofmann et al., 1996) . Whether common mechanisms exist for Rb in preventing protein degradation remain to be seen. Recently, ARF was found to inhibit the E3 ubiquitin ligase activity of mdm2 (Honda and Yasuda, 1999) ; it is possible that Rb inhibits the E3 ligase activity of mdm2 like ARF. It would also be of great interest to determine whether the binding of ARF and Rb to mdm2 are mutually exclusive as well as the regulation of such interactions. What distinguishes the interaction of Rb and mdm2 (and p53 in a trimeric complex) from the interaction of ARF and mdm2 is that the trimeric complex, as we shall see later, selectively modulates p53 functions, whereas in the ARF-mdm2 complex, ARF merely abrogates the inhibitory eects of mdm2 and p53 remains active.
The mdm2-Rb interaction and its eect on the apoptotic ability of p53
The ability of mdm2 to inhibit the activity of p53 is arguably the most important role of mdm2 as the knock-out mice studies showed that mdm2 knock-out mice are embryonic lethal but p53 and mdm2 double knock-out mice develop to term (de Oca Luna et al., 1995; Jones et al., 1995) . Since one of the most important functions of p53 is its ability to induce apoptosis in response to DNA damage, it is likely that one of the critical roles of mdm2 would be to inhibit p53-induced apoptosis. Using DNA laddering assays to show apoptosis and¯ow cytometric methods to quantify apoptosis, it was demonstrated that Rb could overcome the anti-apoptotic function of mdm2 on p53 in the trimeric complex (Hsieh et al., 1999) . To investigate whether the eect of Rb on the stability and the apoptotic function of p53 was mediated by Rb interacting proteins such as the transcription factor E2Fs, three Rb mutants (Figure 3 ) which contained the de®ned protein-protein interaction domains (pocket domains A, B and C) of Rb were used in the study (Hsieh et al., 1999) . It was demonstrated that in addition to wild type Rb, only the two Rb mutants which contained the C-pocket, could overcome the anti-apoptotic function of mdm2 on p53-induced apoptosis; indicating the requirement for mdm2 binding. Although a small part of the C-pocket domain is required together with the A and B pocket domains to bind to the transcription factor E2F, the Cpocket domain mutant pRb(792 ± 928) used in the study does not bind to E2F1 on its own (Hsieh et al., unpublished data) . All these suggest that neither the LXCXE motif containing proteins nor E2F are mdm2 bridges the tumour suppressors, p53 and Rb DBS Yap et al required for Rb to overcome the anti-apoptotic function of mdm2 on p53 induced apoptosis. Furthermore, as the C-pocket Rb mutant pRb(792-928) has been shown to be inactive in the suppression of cell growth in Saos-2 cells (Welch and Wang, 1995) , this argues that the eect observed in the study was also independent of the cell cycle arrest function of Rb. Hence, this demonstrated that the binding of the Cpocket of Rb to mdm2 is sucient in the trimeric complex for p53 to induce apoptosis while still in complex with mdm2. The C-pocket of Rb can also bind c-Abl so it is possible that Rb might bring c-Abl to a p53-mdm2 complex and thus interfere with the apoptotic function of p53. Recent studies have shown that c-Abl can interact with p53 directly to enhance the transactivation function of p53 and mediate p53-dependent cell cycle arrest in response to DNA damage (Goga et al., 1995; Yuan et al., 1996) . p53 interacts with the proline rich region of c-Abl located at its C-terminus and hence should not interfere with the kinase activity of cAbl (Goga et al., 1995) . This contrasts with the c-Abl and Rb interaction since Rb binds to the ATP lobe of c-Abl (residues 205 ± 307) and inhibits its kinase activity (Welch and Wang, 1993) . As the ability of cAbl to induce apoptosis requires its tyrosine kinase activity and is independent of p53 (Yuan et al., 1997) , even though Rb might bring c-Abl to p53, the c-Abl is inactive in inducing apoptosis. Thus it is unlikely that a c-Abl/Rb interaction is mediating the Rb regulation of p53-induced apoptosis. Based on these arguments, it is more probable that the Rb-mdm2 interaction is responsible for the Rb mutant pRb(792 ± 928) overcoming the anti-apoptotic function of mdm2 on p53-induced apoptosis. Thus, the ability of Rb to counteract the negative eects of mdm2 on both the apoptotic function and stability of p53 provided a molecular explanation of how the two most important tumour suppressors may cooperate to prevent tumours.
Uncoupling of the apoptotic function of p53 from its transactivation but correlating it with its transrepression
One of the most important tumour suppressor functions of p53 is its ability to induce apoptosis; the mechanisms through which p53 induces apoptosis remain one of the most actively studied areas of p53 biology. As a transcription factor, p53 has been shown to induce expression of many genes which are involved in inducing apoptosis such as Bax and IGF-BP3 (Buckbinder et al., 1995; Miyashita and Reed, 1995) . Elsewhere it was reported that the proline-rich region of p53 was required for apoptosis (Walker and and this correlated with transrepression as well as the transactivation of a speci®c gene, termed PIG3 (Venot et al., 1998) . It has therefore been suggested that the transactivation function of p53 is important for its apoptotic function. This hypothesis was further supported by various studies using transactivation competent and defective mutants of p53 in transient transfection assays. However, the situation was complicated when two contradictory results were obtained using the same mutant of p53. White et al. working in BRK (Baby Rat Kidney) cells expressing E1A with a transactivation defective mutant p53, p53(Gln22, Ser23), demonstrated that the transactivation function of p53 is required for its apoptotic function (Sabbatini et al., 1995b) . In contrast, using the same p53 mutant, Oren and colleagues were able to show that in HeLa cells this mutant p53 is as active as wild type p53 to induce apoptosis (Haupt et al., 1995) . Figure 3 The functional domains of Rb. Full-length and the mutants used in the study (Hsieh et al., 1999) mdm2 bridges the tumour suppressors, p53 and Rb DBS Yap et al Furthermore, studies using transcription-defective mutant p53 dl214, which has a truncation into its central DNA binding domain, showed this mutant to be able to induce apoptosis in HeLa cells further arguing that the apoptotic function of p53 can be separated from its transactivation function (Haupt et al., 1995) . This view was corroborated by recent studies using dierent p53 mutants. One such mutant, p53(175pro), is able to transactivate many of the p53-responsive promoters to a similar extent as wild type p53 but when it was transfected into two p53-null cell lines Saos-2 and H1299, it failed to induce apoptosis (Rowan et al., 1996) . Similar results were obtained with another p53 mutant, p53(143Ala) (Friedlander et al., 1996) . Detailed studies illustrated that although these two p53 mutants transactivate most p53-responsive promoters such as those of mdm2 and p21 cip1/waf1
, they failed to transactivate promoters of bax and IGF-BP3 which are both implicated in the induction of apoptosis (Friedlander et al., 1996; Ludwig et al., 1996) . These results would then argue that the transactivation function of p53 is still required for its apoptotic function but most important of all, that apoptosis depends on the promoter speci®city of p53. Nevertheless, the induction of apoptosis in response to DNA damage with the same kinetics in thymocytes of bax knock out mice as in those of wild type mice (Knudson et al., 1995) would argue that the ability of p53 to transactivate bax may be uncoupled from its ability to induce apoptosis since it is known that p53 plays a crucial role in DNA damage induced apoptosis in thymocytes (Clarke et al., 1993; Lowe et al., 1993) . Transcription-independent apoptosis mediated by p53 has also been reported in the cells treated with actinomycin D (Caelles et al., 1994) .
Much of the diculty in drawing clear conclusions as to whether the transactivation function of p53 can be uncoupled from its apoptotic function comes from the fact that many dierent p53 mutants were used and the studies were conducted in dierent cell types under dierent conditions (Ko and Prives, 1996) . It has been argued recently that dierent cell types could have dierent responses to p53-induced apoptosis since mdm2 inhibited p53-induced apoptosis in H1299 cells but not in HeLa cells . Thus, in order to clarify that the transactivation and apoptotic functions of p53 are separable, it is important to demonstrate a discordance of these two dierent functions of wild type p53 in the same type of cells.
The novel trimeric complex of Rb, mdm2 and p53 reported recently provided such an opportunity. Within the same type of cells, the transactivation function of p53 could be regulated by the absence or presence of mdm2 and was unaected by the co-expression of Rb. More importantly, co-expression of Rb speci®cally overcame the anti-apoptotic function of mdm2 on p53-mediated apoptosis whereas mdm2 remained inhibitory on the transactivation of p53. This dichotomous eect of Rb provided an ideal system in which to demonstrate the dissociation of the apoptotic function of wild type p53 from its transactivation function. It was shown that although p53 in the trimeric complex is as competent to induce apoptosis as wild type p53 alone, it showed impaired ability to transactivate promoters such as Bax and p21 waf1/cip1 , mdm2 and cyclin G (Hsieh et al., 1999) . Furthermore, as mdm2 remained in complex with p53, this means that the transactivation domain of p53 remains occluded by mdm2 explaining why p53 is transactivationally incompetent in the trimeric complex. Thus it is clear that in the context of the trimeric complex, the apoptotic function of p53 can be uncoupled from its transactivation function.
Apart from being a transactivator, p53 has been demonstrated to act as a repressor of many promoters which contain a TATA box but lack a p53 binding site (Ko and Prives, 1996) . Unlike its transactivation function, hardly anything is known of the mechanism of transrepression by p53. It has been reported that p53 can bind to components of the basal transcription machinery and one such component is the TATA box binding protein (TBP) (Seto et al., 1992) . Both N and C-terminal parts of p53 have been implicated in the binding of TBP and p53-mediated transrepression Subler et al., 1994) . Other proteins such as TAFII40 and TAFII60 which are involved in controlling general transcription, have also been shown to interact with p53 and interestingly both TAFII40 and TAFII60 bind to a similar region on p53 as mdm2 (Thut et al., 1995) . Mutations in mdm2 binding sites of p53 (Ser 22 and 23) abolish both its transrepression function as well as its interaction with TAFII40 and TAFII60 (Sabbatini et al., 1995b) , suggesting that the interaction with TAFs maybe important for the transrepression function of p53. In addition, it has also been shown recently that mdm2 can repress transcription independent of p53 (Thut et al., 1997) .
Although many cellular promoters can be transrepressed by p53 in vitro, very few target genes have so far been identi®ed in vivo. Nevertheless, there is evidence to suggest that the transrepression function of p53 is associated with its ability to induce apoptosis. One such example is the p53 mutant, p53(175Pro). This mutant retains its transactivation function for some p53-responsive promoters such as mdm2 and p21 cip1/waf1 , but is defective in inducing apoptosis as well as mediating transrepression (Crook et al., 1994; Rowan et al., 1996) . Using a selection of dierent p53(175) mutants, Ryan and Vousden (1998) showed that some mutants retained their apoptotic function, despite being impaired for bax and IGF-BP3 induction. All apoptotically-competent mutants, however, were active for transrepression of c-fos promoter in vitro. Furthermore, studies have also shown that antiapoptotic proteins such as Bcl-2 and adenovirus E1B 19-kD protein can inhibit p53-mediated apoptosis. Interestingly, these two proteins can also inhibit p53-mediated transrepression but not transactivation (Sabbatini et al., 1995a; Shen and Shenk, 1994) . These results would be consistent with the transrepression function of p53 being associated with its apoptotic function. However, some critics argued that the reduced transcriptional activity of the reporters used in the in vitro assays was simply a consequence of p53-induced apoptosis.
To address this issue and clearly demonstrate that the transrepression function of p53 correlates with its apoptotic function, a cell-permeable cysteine protease inhibitor zVAD-FMK was used to inhibit p53-induced apoptosis (Hsieh et al., 1999; Sabbatini et al., 1997) . Under the same conditions, zVAD-FMK did not have mdm2 bridges the tumour suppressors, p53 and Rb DBS Yap et al any eect on the transrepression function of p53 or the trimeric complex of p53, mdm2 and Rb(792 ± 928). This result would argue that the transrepression function of p53 detected in the assay was not a consequence of cell death. This result also allowed the conclusion that the Rb-mdm2-p53 trimeric complex is active in p53-mediated apoptosis and transrepression but not transactivation. Together with previous data, it provided the ®rst illustration that the apoptotic function of wild type p53 is linked with its transrepression function without the use of p53 mutants (Figure 4 ).
The future
In summary, we have shown and argued how the apoptotic function of p53 may be governed by a physiological regulator such as Rb through modulation of mdm2 in a trimeric complex. Although the transactivation function of p53 clearly can contribute to its apoptotic function but in light of the Rb-mdm2-p53 trimeric complex, we have also furnished evidence pointing towards the fact that the apoptotic ability of p53 can be uncoupled from its ability to act as a transactivator but not as a transrepressor. We do not yet know how this novel Rb-mdm2-p53 trimeric complex is regulated in vivo. We also do not know how can it stabilize p53 and repress gene expression, nor do we know which genes can be repressed by it, but the properties of the complex suggest potential mechanisms through which p53 may induce apoptosis. It has been reported Bcl-2 expression can be repressed by p53 (Miyashita et al., 1994) and recently MAP4 (microtubule associated protein 4) (Murphy et al., 1996) , another target which is subject to speci®c transrepression by p53 was described. Consistent with the fact that repression may be involved in p53-mediated apoptosis, overexpression of Bcl-2 and MAP4 blocks p53-mediated apoptosis (Chiou et al., 1994; Murphy et al., 1996) . Alternatively, the transrepression of p53 may be linked with its cellular levels and there may be no particular target genes at all. Using inducible cell lines, Chen et al. (1996a) demonstrated that lower levels of p53 cause arrest while higher levels of p53 result in apoptosis. Perhaps it is the ability to stabilize wild type p53 to threshold levels required for apoptosis that is important and the transrepression merely correlates with the levels. Finally it is also possible that the in vitro assay used to measure the transrepression function of p53 is just a sensitive read-out of the cell commitment to death induced by p53. What is evident is that there is a clear correlation between the ability of p53 to induce apoptosis as well as mediate transrepression. It thus remains to be seen whether the answer lies in the genes repressed by p53 or the protein levels of p53. Finding this key may allow us to unlock the molecular secrets of how p53 induces apoptosis, which has for so long remained elusive. 
